Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 5/20 | 0.45 |
| ▸ | RXRB | P28702 | 5/20 | 0.45 |
| ▸ | RXRG | P48443 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 2/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29755981 | 1.00 | AGBL2 (0.47) | AGBL2NOS3NOS2RXRARXRB | |
| Hydrochloric Acid SCHEMBL17653893 | 0.98 | AGBL2 (0.46) | AGBL2NOS3NOS2RXRARXRB | |
| SCHEMBL17396700 | 0.98 | AGBL2 (0.46) | AGBL2NOS3NOS2RXRARXRB | |
| SCHEMBL17396756 | 0.92 | AGBL2 (0.46) | AGBL2NOS3NOS2RXRARXRB | |
| SCHEMBL29894312 | 0.85 | NOS3 (0.49) | NOS3NOS2ALDH1A1GAAL3MBTL1 | |
| Lithium Ion SCHEMBL17396698 | 0.85 | NOS3 (0.44) | NOS3NOS2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL3188772 | 0.85 | NOS3 (0.49) | NOS3NOS2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL29080949 | 0.83 | CTSK (0.47) | NOS3NOS2RXRARXRBRXRG | |
| SCHEMBL15505079 | 0.81 | ALDH1A1 (0.48) | NOS3NOS2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL4326563 | 0.80 | ALDH1A1 (0.44) | NOS3NOS2ALDH1A1GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360121-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-10-31 | — | — | US | disclosed |
| US-11958849-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230124815-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-20 | — | — | US | disclosed |
| CN-114805346-A | Heterocyclic derivative, preparation method and application thereof | 成都硕德药业有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-114761082-A | Azepane derivatives | 日本化学药品株式会社 | 2022-07-15 | — | — | CN | disclosed |
| US-11370786-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2021065898-A1 | AZEPAN DERIVATIVE | 日本ケミファ株式会社 | 2021-04-08 | — | — | WO | disclosed |
| CN-107074805-B | GLS1 inhibitors for the treatment of disease | 德州大学系统董事会 | 2021-02-26 | — | — | CN | disclosed |
| US-20200407353-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-12-31 | — | — | US | disclosed |
| US-10766892-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-09-08 | — | — | US | disclosed |
| US-10344025-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-07-09 | — | — | US | disclosed |
| US-9809588-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170291895-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-10-12 | — | — | US | disclosed |
| EP-3164394-A2 | GLS1 INHIBITORS FOR TREATING DISEASE | Board of Regents, The University of Texas System (US) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016051193-A1 | COMPOUNDS USEFUL AS CSF1 MODULATORS | REDX PHARMA PLC (GB) | 2016-04-07 | — | — | WO | disclosed |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-14 | — | — | US | disclosed |
| WO-2016004404-A2 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016004404-A2 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | WO | disclosed |
| CN-102026978-A | Pyridine compounds | HOFFMANN LA ROCHE | 2011-04-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344025-B2 | GLS1 inhibitors for treating disease | GLS2, GLS, GLG1 | AGBL2 674/4885NOS3 1868/4885NOS2 1711/4885 |
| US-20240360121-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | AGBL2 674/4885NOS3 1868/4885NOS2 1711/4885 |
| US-20230124815-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | AGBL2 674/4885NOS3 1868/4885NOS2 1711/4885 |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | AGBL2 674/4885NOS3 1868/4885NOS2 1711/4885 |
| US-10766892-B2 | GLS1 inhibitors for treating disease | GLS2, GLS, GLG1 | AGBL2 674/4885NOS3 1868/4885NOS2 1711/4885 |
| US-11370786-B2 | GLS1 inhibitors for treating disease | GLS2, GLS, GLB1 | AGBL2 606/4885NOS3 2395/4885NOS2 2366/4885 |
| US-11958849-B2 | GLS1 inhibitors for treating disease | GLS2, GLS, GLG1 | AGBL2 674/4885NOS3 1868/4885NOS2 1711/4885 |
| US-20200407353-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | AGBL2 674/4885NOS3 1868/4885NOS2 1711/4885 |
| US-20170291895-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | AGBL2 674/4885NOS3 1868/4885NOS2 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.